1-(methoxymethyl)-4-methyl-1H-pyrazole | 1803562-68-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(methoxymethyl)-4-methyl-1H-pyrazole
• 英文别名: 1-(methoxymethyl)-4-methylpyrazole
• CAS: 1803562-68-6
• 化学式: C₆H₁₀N₂O
• mdl: MFCD28246286
• 分子量: 126.16
• InChiKey: WSTFFWKWDPXUJD-UHFFFAOYSA-N

物化性质

• 沸点：
  180.6±23.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：Aronov Alex

  公开号：US20120040950A1

  公开（公告）日：2012-02-16

  The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及用作PI3K抑制剂的化合物，特别是PI3Kγ的抑制剂。本发明还提供包含该化合物的药学上可接受的组合物，并提供使用该组合物治疗各种疾病、病况或疾病的方法。
• COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES
  申请人：BEIJING HANMI PHARMACEUTICAL CO., LTD.

  公开号：US20160229865A1

  公开（公告）日：2016-08-11

  The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).

  本发明涉及一种抑制布鲁顿酪氨酸激酶（BTK）和/或Janus激酶3（JAK3）活性的化合物，该化合物的制药组合物，其制药应用，使用该化合物抑制BTK和/或JAK3活性的方法以及使用该化合物治疗和/或预防哺乳动物（尤其是人类）中BTK和/或JAK3介导的疾病或疾病的方法。该化合物的结构式（I）如下：
• PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20190153006A1

  公开（公告）日：2019-05-23

  Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
• US8466288B2
  申请人：——

  公开号：US8466288B2

  公开（公告）日：2013-06-18
• US9840517B2
  申请人：——

  公开号：US9840517B2

  公开（公告）日：2017-12-12